Published on June 28, 2005 at 8:27 AM
In a review of its popular impotence treatment Viagra, Pfizer announced on Monday that it had found no evidence of increased risk of blindness among patients taking the erectile dysfunction drug.
Pfizer, the world's largest drugmaker, however says it is in discussion with U.S. regulators about revising the Viagra label to reflect rare reports of a serious ocular condition known as non-arteritic anterior ischemic optic neuropathy (NAION) in some men who have used the medicine.
Even though the U.S. Food and Drug Administration also concluded that there appeared to be no causal relationship between Viagra and NAION, Pfizer has agreed with the agency to include the fact of these reports in the Viagra label to help inform physicians and patients.